TrialNature medicine2025

Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial.

Caicun Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.